U.S. License Holder:
Date of License:
ORENCIA (abatacept) is a selective T cell costimulation modulator indicated for the treatment of:
Adult patients with moderately to severely active rheumatoid arthritis (RA);
Patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA);
Adult patients with active psoriatic arthritis (PsA).
Inter Partes Review ProceedingsPTAB Portal
IPR Case No(s):
U.S. Patent No.
8,476,239 (Stable Protein Formulations)
Bristol-Myers Squibb Co.
Momenta Pharmaceuticals, Inc.; Mylan GmbH; Mylan Inc.; Mylan Institutional LLC; Mylan Ireland Ltd.; Mylan NV; Mylan Pharmaceuticals Inc.
§ 102 Challenge
§ 103 challenge
Claim Types Challenged Under § 103
Formulation Other (Article of Manufacture)
§ 103 Challenge Instituted
Final Written Decision Issued
Federal Circuit Appeal(s)
Final Written Decision (No Instituted Claim Found Unpatentable); Appeal to Federal Circuit Dismissed for Lack of Standing/Jurisdiction and Mootness